retatrutide phase 2 trial type 2 diabetes weight loss 2024 TRIUMPH-4 Results: Are We Witnessing a New Era in Obesity Management? Weight loss with retatrutide as

In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise

[16] While some participants in clinical studies have reported menstrual changes, these are generally attributed to the metabolic effects of weight loss rather than direct drug action on reproductive tissues, and are not classified as common adverse effects in the UK product information for GLP-1 medications

Both are effective, but their approaches vary

Signs include rash, swelling of the face or throat, or difficulty breathing, which require urgent medical attention

Tirzepatide before and after transformations become evident, with better energy levels and improved overall health